India’s Glenmark Confirms Abbott Sued It Over Tarka Generic (India)
This article was originally published in PharmAsia News
Executive Summary
India's Glenmark Pharmaceuticals confirms Abbott Laboratories has sued it in the United States to block its FDA application for a generic version of Tarka (trandolapril, verapamil hydrochloride) for treating hypertension. Glenmark believes it was the first to file for a generic, the first for the company, but Abbott said the application violates its patent. Tarka has generated $100 million in U.S. sales for Abbott. (Click here for more ) "Glenmark Confirms Abbott Suit Against Tarka Generic" Economic Times (India) (12/13/07)